Maxillofacial Plastic and Reconstructive Surgery

Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지

THE ANTICANCER EFFECT OF PACLITAXEL($Taxol^{(R)}$) IN ORAL SQUAMOUS CELL CARCINOMA XENOGRAFT

이종 이식된 구강편평세포 암종에서 Paclitaxel ($Taxol^{(R)}$)의 항암 효과

  • Kim, Ki-Hwan (Dept. of Oral & Maxillofacial Surgery, School of Dentistry, Dankook University) ;
  • Kim, Chul-Hwan (Dept. of Oral & Maxillofacial Surgery, School of Dentistry, Dankook University) ;
  • Han, Se-Jin (Dept. of Oral & Maxillofacial Surgery, School of Dentistry, Dankook University) ;
  • Lee, Jae-Hoon (Dept. of Oral & Maxillofacial Surgery, School of Dentistry, Dankook University)
  • 김기환 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 김철환 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 한세진 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 이재훈 (단국대학교 치과대학 구강악안면외과학교실)
  • Published : 2006.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

The treatment for oral and maxillofacial carcinoma with chemotherapeutic agents is evaluated by many effective methods to reduce the tumor mass and cancer cell proliferation. However these chemotherapy have many serious side effects, such as bone marrow suppression, renal toxicity, G-I troubles. Therefore a possible approach to develop a clinically applicable chemotherapeutic agent is to screen anticancer activity of Taxol which is known to have very little side effect and have been used to breast cancer and ovarian carcinoma. Taxol is a new anti-microtubular anti-cancer agent extracted from the bark of the Pacific yew, Taxus brevifolia. Paclitaxel(Taxol) acts by promoting tubulin polymerization and over stabilizing microtubules agianst depolymerization. Despite the constant improvements of methods of the cancer treatment especially chemotherapy, the rate of cancer metastasis and recurrent are not decreased. Thus the investigation of new drug which have very little side effect and a possible clinically application continues to be a high priority. Considering that the Taxol have shown very effective chemotherapeutic agent with relatively low toxicity in many solid tumors, it deserves to evaluate its efficacy in oral squamous cell carcinoma. In this study, to investigate the in-vivo and in-vitro anti-cancer efficacy of Taxol in oral squamous cell carcinoma and lastly, the potency of Paclitaxel in the clinical application for oral cancer was evaluated. In vivo study, after HN22 cell line were xenografted in nude mice, the growth of tumor mass was observed, 3 mg/Kg taxol was injected intraperitoneally into nude mice containing tumor mass. The methods of these study were measurement of total volume of tumor mass, histopathologic study, immunohistochemical study, drug resistance assay, growth curve, MTT assay, flow cytometry, cDNA microarray in vivo and in vitro. The results were obtained as following. 1. The visual inspection of the experimental group showed that the volume of the tumor mass was slightly decreased but no significant difference with control group. 2. Ki-67 index was decreased at weeks 4 in experimental group. 3. Microscopic view of the xenografted tumor mass showed well differentiated squamous cell carcinoma and after Taxol injection, some necrotic tissue was seen weeks 4. 4. The growth curve of the tumor cells were decreased after 1day Taxol treatment. 5. According to the MTT assay, HN22 cell line showed relative drug resistancy above $5\;{\mu}g/ml$ concentrations of Taxol. 6. In drug resistance assay, the decrease of cell counts was seen relatively according to concentration. 7. In Flow cytometry, G2M phase cell arrests were seen in low concentration of the Taxol, while S phase cell arrests were seen in high concentration of the Taxol. 8. Using cDNA microarray technique, variable gene expression of ANGPTL4, TXNRD1, FAS, RRAGA, CTGF, CYCLINEA, P19, DUSP5, CEBPG, BTG1 were detacted in the oral squamous cell carcinoma cell after taxol treatment. In this study paclitaxel is effective against oral squamous cell carcinoma cell lines in vitro, but week effect was observed in vivo. So we need continuous study about anticancer effect of taxol in vivo in oral squamous cell carcinoma.

Keywords

References

  1. Vikran B, Strong E, Shah J et al : Failure at the primary site-following multimodality treatment for advanced head and neck cancer. Head Neck Surg 6 : 720, 1984 https://doi.org/10.1002/hed.2890060303
  2. Jacobs J, Fu K, Lowry L : Five-year results of cisplatin and fluorouracil in head and neck carcinoma. Arch Otolaryngol Head Neck Surg 117 : 288, 1991 https://doi.org/10.1001/archotol.1991.01870150056006
  3. Mayers EN : Cancer of the head and neck. 2nd ed. New York, Churchill Livingstone, 1989
  4. Jonathan CI, Alan B : Oncogenes in head and neck cancer, Laryngoscope 103 : 42, 1993
  5. Peterson LJ : Principles of oral and maxillofacial surgery. Philadelphia, J.B. Lippincott, 1992
  6. Wani MC, Taylor HL, Wall ME : Plant antitumor agents VI, The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 893 : 2325, 1971
  7. Bahalla K, Ibrado AM, Tourkina E et al : Taxol induces internucleosomal DNA fragmentation associated with programed cell death in human myeloid leukemia cells. Leukemia 7(4) : 563, 1993
  8. Crossin KL, Carney DH : Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 27 : 314, 1981
  9. Hamel E, Del Campo AA, Lowe MC : Interactions of taxol, microtubule associated proteins and guanine nucleotid in tubulin polymerization, J Biol Chem 256 : 1887, 1981
  10. Rowinsky EK. Cazenave LA, Donehower RC : Taxol ; A novel investigational antimicrotubule agent. J Natl Cancer Inst 82 : 1247, 1990 https://doi.org/10.1093/jnci/82.15.1247
  11. Rowinsky EK, Eisenhauer EA, Chaudhry V et al : Cinical toxicities encountered with paclitaxel ($Taxol^{\circledR)$). Sem Oncolog 20(4) : 1, 1993
  12. Luo D, Cheng SC, Xie X et al : Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protien levels. Tumour Biol 20 : 331, 1999 https://doi.org/10.1159/000030097
  13. Huang M, Liu G : The study of innate drug resistance of human hepatocellula carcinoma Bel 7402 cell line. Cancer Left 135 : 97, 1999
  14. Parekh H, Wiesen H, Simpkins H : Acquisition of taxol resistance via P-glycoprotein and non-P-glycoproteinmediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 53 : 461, 1997 https://doi.org/10.1016/S0006-2952(97)83383-7
  15. Bates SE, Zhan Z, Dickstein B et al : Reversal of multidrug resistance, J Hematother 3 : 219, 1994 https://doi.org/10.1089/scd.1.1994.3.219
  16. Kavallaris M, Kuo DY, Burkhart CA et al : Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific betatubulin isotypes. J Clin Invest 100 : 1282, 1997 https://doi.org/10.1172/JCI119642
  17. Gazitt Y, Rothenberg ML, Hilsenbeck SG et al : Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 13 : 839, 1998
  18. Huang Y, Ibrado AM, Reed JC et al : Co-expression of several molecular mechanisims of multidrug resistance and their significance for Paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11 : 253, 1997 https://doi.org/10.1038/sj.leu.2400557
  19. Liu JR, Fletcher B, Page C et al : Bcl-xl is expressed in ovarian carcinom and modulated cemohterapy-induced apoptosis. Gynecol Oncol 70 : 398, 1998 https://doi.org/10.1006/gyno.1998.5125
  20. Jang SH, Wientjes MG, Au JL : Kinetics of P-glycopretien mediated efflux of paclitaxel. J Pharmacol Exp Ther 298 : 1236, 2001
  21. Kondratov RV, Komarov PG, Becker Y et al : Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotien. Proc Natl Acad Sci USA 98 : 14078, 2001
  22. Siegel DS, Zhang X, Feinman R et al : Hexamethylene bisacetamide induces programmed cell death(apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc Natl Acad Sci USA 95 : 162, 1998
  23. Giannakakou P, Sackett DL, Kang YK et al : Paclitaxelresistance human ovarian cancer cells have mutant betatubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272 : 17118, 1997
  24. Strobel T, Kraeft SK, Chen LB et al : BAX expression is associated with enhanced intracellular accumulation of paclitaxel ; a novel role for BAX during chemotherapyinduced cell death. Cancer Res 58 : 4776, 1998
  25. Janicke RU, Sprengart ML, Wati MR et al : Caspase3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273 : 9357, 1998 https://doi.org/10.1074/jbc.273.16.9357
  26. Huang Y, Ray S, Reed JC et al : Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxolinduced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42 : 73, 1997 https://doi.org/10.1023/A:1005777219997
  27. Panvichian R, Orth K, Day ML et al : Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation ; a potential early step in drug resistance. Cancer Res 58 : 4667, 1998
  28. Vokes GE, Haraf DJ, Stenson K et al : The role of paclitaxol in the treatment of head and neck cancer. Sem Oncolog 22(5) : 8, 1995
  29. Manfredi J, Horwitz SB : Taxol ; An antimitotic agent with a new mechanism of action. Pharmacol Ther 25 : 83, 1984 https://doi.org/10.1016/0163-7258(84)90025-1
  30. Rowinsky E, Donehower RC, Jones RJ et al : Microtutule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48 : 4093, 1988
  31. Holmes FA, Walters RS, Theriault RL : Phase II trial of taxol ; An active drug in metastatic breast cancer. J Natl Cancer Inst 83 : 1797, 1991
  32. Seidman A, Reichman B, Crown J : Activity of taxol with recombinant granulocyte colony-stimulating factor as first chemotherapy of patients with metastatic breast cancer. Proc Am Soc Clin Onclo 11 : 59, 1992
  33. Jensen CG, Davision EA, Bowser SS, et al : Primary cilia cycle in PtKl cells ; Effects of colcemid and taxol on cilia fomation and resorption. Cell Motil Cytoskeleton 7(3) : 187, 1987 https://doi.org/10.1002/cm.970070302
  34. Raniney We, Kramer RE, Mason JI et al : The effects of taxol, a microtutule-stabilizing drug, steroidogenic cells. J Cell Physiol 123 : 17, 1985
  35. Cazey TE, Kimmel KA, Schwartz DR et al : Antibodies to human squamous cell carcinoma, Otolaryngol Head Neck Surg 91 : 482, 1983 https://doi.org/10.1177/019459988309100503
  36. Giovanella BC, Steholin JS, Willams Jr LJ : Heterotransplantation of human malignant tumors in "nude"thymusless mice II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J National Cancer Inst 52(3) : 921, 1974 https://doi.org/10.1093/jnci/52.3.921
  37. Kelner MJ, Mcmorris TC, Estes L et al : Noneresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res 15 : 867, 1995
  38. Kubota T, Matsuzaki SW, Hoshiya Y et al : Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J surg Oncolog 64 : 115, 1997 https://doi.org/10.1002/(SICI)1096-9098(199702)64:2<115::AID-JSO5>3.0.CO;2-E
  39. Yamori T, Sato S, Chikazwa H et al : Antitumor efficacy of paclitaxel against human lung cancer xenograft. Jpn J cancer Res 88 : 1205, 1997 https://doi.org/10.1111/j.1349-7006.1997.tb00350.x
  40. Guo B, Villeneuve DJ, Hembruff SL et al : Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidance suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Research and Treatment 85 : 31, 2004 https://doi.org/10.1023/B:BREA.0000021046.29834.12
  41. Hennequin C, Giocanti N, Favaudon V : Interaction of ionizing radiation with paclitaxel($Taxol^{\circledR)$ ) and docitaxel(Taxolate) in Hela and SQ20B cells. Cancer Res 56 : 1842, 1996
  42. Shikani AH, Domb AJ : Polymer chemotherapy for head and neck cancer. The Layngoscope 110 : 907, 2000 https://doi.org/10.1097/00005537-200006000-00004
  43. Scholzon T, Gerdes J : The Ki-67 protein ; from the known and the unknown. J Cell Physiol 182(3) : 311, 2000 https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
  44. Mckormick D : Detection of the Ki-67 antigen in fixed and wax-embeded sections with the monoclonal antibody Ki-67(MIB-1). Histopathology 22 : 335, 1993 https://doi.org/10.1111/j.1365-2559.1993.tb00132.x
  45. Alldy MC, Scudlero DA, Monks A : Feasibility of screening with panels of human tumor cell lines using a micro culture tetrazolium assay. Cancer Res 48 : 589, 1988
  46. Budach V, Bamberg M, Scheulen E : Preclinical chemosensitivity studies with human soft tissue sarcomas in nude mice. Contr Oncol 26 : 168, 1987
  47. Hamburger AW, Salmon SE : Primary bioassay of human tumor stem cells, Science 197 : 461, 1997
  48. Sobottka SB, Beerger MR : Assessment of antineoplastic agents by MTT assay ; partial under estimation of antiproliferative properties. Cancer Chemother Pharmacol 30(5) : 385, 1992 https://doi.org/10.1007/BF00689967
  49. Ruben RL, Neubauer RH : Semiautomated colormetic assay for in vitro screening of anticancer compounds. Cancer Treat Rep 71 : 1141, 1987
  50. Chamichel J : Evaluation of atetrazolium-based semiautomated colormatric assay assesment of chemosensitivity testing. Cancer Res 47 : 936, 1987
  51. Kaufmann SH : Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and ohter cytotoxic anticancer drugs; a cautionary tale. Cancer Res 49 : 5870, 1989
  52. Walker PR, Smith C, Youdale T et al : Topisomerase II - reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 51 : 1078, 1991
  53. Yoshioka A, Tanaka S, Hiraoka O et al : Deoxyribonucleoside triphosphate imbalance. 5-fluorodeoxyridine- induced DNA double strand bresks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 262 : 8235, 1987
  54. Lorico A, Toffoli G, Boiocchi M et al : Accumulation of DNA strand breaks in cells exposed to methoterxate or N- 10-propargyl-5,8-dideazafolec acid. Cancer Res 48 : 2036, 1998
  55. Searle J, Lawson TA, Abbott PJ et al : An electron microscopy study of the mode of cell death induced by cancer- chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Path 116 : 129, 1975 https://doi.org/10.1002/path.1711160302
  56. Warrell RP : in 'Cancer;Principles and Practice of Oncology' J.V.T. Devita, S. Hellman, and S.A. Rosicberg, Eds. pp.2128
  57. Nagata S, Golstein P : The Fas death factor. Science 267 : 1449, 1995 https://doi.org/10.1126/science.7533326
  58. Verheij M, Bose R, Lin X et al : Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380.6569 : 75, 1996 https://doi.org/10.1038/380075a0
  59. Woods CM, Zhu J, McQueney PA et al : Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1(5) : 506, 1995
  60. Brown PO, Botstein D : Exploring the new world of the genome with DNA microarrays. Nature Genetics 21 : 33, 1999 https://doi.org/10.1038/4462
  61. Duggan DJ, Bittner M, Chen Y et al : Expression profiling using cDNA microarrays. Nature Genetics 21 : 10, 1999 https://doi.org/10.1038/4434
  62. Lemieux B, Aharoni A, Schena M : Overview of DNA chip technology. Mol Breed 4 : 277, 1998 https://doi.org/10.1023/A:1009654300686
  63. Schena M, Shalon D, Davis RW et al : Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 : 467, 1995 https://doi.org/10.1126/science.270.5235.467